Skip to content

Effectiveness of the Paediatric Electronic quality of Life Instrument for Childhood Asthma in the Netherlands (Pelican) in medical care.

Effectiveness of the Paediatric Electronic quality of Life Instrument for Childhood Asthma in the Netherlands (Pelican) in medical care. - PELICAN II project

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32734
Enrollment
270
Registered
2010-01-21
Start date
2010-12-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

The intervention in the two studies is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma.

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: * age 6 to 12 years * physician-diagnosed asthma * child is treated for their asthma by the recruiting physician * use of inhaled asthma medication for at least six weeks during the previous year

Exclusion criteria

Exclusion criteria: * comorbid condition that significantly influences HRQL * child does not master the Dutch language sufficiently * not being able to attend a regular school class

Design outcomes

Primary

MeasureTime frame
Asthma-specific health related quality of life of the children as measured with the Pediatric Asthma Quality of Life Instrument

Secondary

MeasureTime frame
Secondary outcomes are measures of asthma control, asthma medication use, lung function, NO, asthma symptoms, costs (i.e. program costs, direct medical and indirect costs), and satisfaction with delivered health care in children as well as in their parents and physician. Next, facilitators and barriers of implementation of the Pelican instrument in primary and secondary care are assessed. To address this, the process of the implementation of the instrument in both randomised trials will be evaluated. Also the caregivers (i.e., parents) health related quality of life is a secondary outcome.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)